Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for MDxHealth (MDXH) over the last 4 years, with Q3 2025 value amounting to -$775000.0.

  • MDxHealth's Cash from Investing Activities fell 586153.85% to -$775000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.6 million, marking a year-over-year decrease of 119109.16%. This contributed to the annual value of -$1.6 million for FY2024, which is 5838.21% up from last year.
  • Latest data reveals that MDxHealth reported Cash from Investing Activities of -$775000.0 as of Q3 2025, which was down 586153.85% from -$19.6 million recorded in Q2 2025.
  • MDxHealth's 5-year Cash from Investing Activities high stood at $13000.0 for Q1 2025, and its period low was -$19.6 million during Q2 2025.
  • Moreover, its 4-year median value for Cash from Investing Activities was -$242000.0 (2021), whereas its average is -$2.5 million.
  • Over the last 5 years, MDxHealth's Cash from Investing Activities had its largest YoY gain of 586153.85% in 2025, and its largest YoY loss of 586153.85% in 2025.
  • Over the past 4 years, MDxHealth's Cash from Investing Activities (Quarter) stood at -$232000.0 in 2021, then tumbled by 85.78% to -$431000.0 in 2022, then surged by 46.87% to -$229000.0 in 2024, then crashed by 238.43% to -$775000.0 in 2025.
  • Its Cash from Investing Activities was -$775000.0 in Q3 2025, compared to -$19.6 million in Q2 2025 and $13000.0 in Q1 2025.